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Abstract 
 
Acidic fibroblast growth factor (FGF1) and neuregulin-1 (NRG1) are growth factors involved in 
cardiac development and regeneration. Microparticles (MPs) mediate cytokine sustained 
release, and can be utilized to overcome issues related to the limited therapeutic protein stability 
during systemic administration. We sought to examine whether the administration of 
microparticles (MPs) containing FGF1 and NRG1 could promote cardiac regeneration in a 
myocardial infarction (MI) rat model. We investigated the possible underlying mechanisms 
contributing to the beneficial effects of this therapy, especially those linked to endogenous 
regeneration. FGF1- and NRG1-loaded MPs were prepared using a multiple emulsion solvent 
evaporation technique. Seventy-three female Sprague-Dawley rats underwent permanent left 
anterior descending coronary artery occlusion, and MPs were intramyocardially injected in the 
peri-infarcted zone four days later. Cardiac function, heart tissue remodeling, revascularization, 
apoptosis, cardiomyocyte proliferation, and stem cell homing were evaluated one week and 
three months after treatment. MPs were shown to efficiently encapsulate FGF1 and NRG1, 
releasing the bioactive proteins in a sustained manner. Three months after treatment, a 
statistically significant improvement in cardiac function was detected in rats treated with growth 
factor-loaded MPs (FGF1, NRG1, or FGF1/NRG1). The therapy led to inhibition of cardiac 
remodeling with smaller infarct size, a lower fibrosis degree and induction of tissue 
revascularization. Cardiomyocyte proliferation and progenitor cell recruitment was detected. 
Our data support the therapeutic benefit of NRG1 and FGF1 when combined with protein 
delivery systems for cardiac regeneration. This approach could be scaled up for use in pre-
clinical and clinical studies. 
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1. Introduction 
Ischemic heart disease is the leading cause of morbidity and mortality worldwide [1]. 
Thus, there has been great interest in novel therapeutic options, such as gene (reviewed 
in [2]) and stem cell therapy (reviewed in [3]), or even direct administration of pro-
angiogenic cytokines [4]. In the case of growth factor-based therapy, although pre-
clinical studies and initial clinical trials had suggested beneficial effects [5, 6], double-
blinded clinical trials with large cohorts of patients failed to validate the efficacy [7-9]. 
These negative findings may have resulted from issues related to growth factor 
selection, monotherapy instead of combinatorial therapy, and/or timing of growth factor 
delivery. Moreover, the therapeutic benefit of directly administered growth factors can 
be limited by the short circulating half-life and high instability of these proteins after 
injection. In this context, new strategies involving injectable biocompatible and 
biodegradable microparticles (MPs), which mediate sustained release of cytokines, 
might offer valuable approaches for overcoming these limitations [10].  
Poly(lactic-co-glycolic acid) (PLGA) is a biopolymer that is FDA-approved for use as a 
drug delivery platform due to its excellent biocompatibility, high safety profile, and 
suitable biodegradation [11]. PLGA MPs were already shown to be useful for growth 
factor delivery [12, 13]. Moreover, we demonstrated the efficacy of treating infarcted 
hearts with PLGA MPs loaded with vascular endothelial growth factor (VEGF), which 
induced neovascularization and reduced cardiac remodeling after myocardial infarction 
(MI) in rats [14]. Indeed, many pre-clinical and clinical studies aimed at repairing 
infarcted heart tissue have explored pro-angiogenic cytokine administration as a means 
to promote tissue revascularization.  
In addition to mediators of angiogenesis, the list of potential therapeutics for cardiac 
regeneration has continued to grow, and the use of factors involved in cardiac 
development, stem cell homing, cardiac differentiation/proliferation, or direct 
cardioprotection could lead to novel approaches for repairing damaged heart (reviewed 
in [4]). In this regard, in vitro studies have shown that adult cardiomyocytes do not 
proliferate under resting conditions, but may divide in response to extracellular 
mitogens, such as periostin [15], acidic fibroblast growth factor (FGF1) [16], and 
neuregulin-1 (NRG1) [17]. These findings have supported a new paradigm, which 
suggests that the heart might be capable of repair and regrowth in response to 
extracellular mitogens. Consistent with this idea, it is known that FGF1 regulates 
cardiac remodeling by exerting a protective and proliferative effect after MI [18, 19]. 
On the other hand, neuregulins play crucial roles in the adult cardiovascular system by 
inducing structural organization of sarcomeres, cell integrity, cell–cell adhesion [20], 
cell survival [21, 22] and angiogenesis [23]. In fact, several studies using animal models 
of heart failure have demonstrated the therapeutic benefits of neuregulins, which 
improved cardiac performance, attenuated disease markers, and prolonged animal 
survival [24, 25]. Furthermore, phase I and II clinical trials for chronic heart failure in 
humans confirmed the favorable effects mediated by neuregulins [26, 27], highlighting 
the therapeutic potential of these growth factors in cardiac repair. 
In this study, we have examined the efficacy of novel MP-based delivery of NRG1 and 
FGF1 in a rat model of MI. Notably, the use of MPs prevented issues related to growth 
factor stability, facilitating sustained treatment in the damaged tissues. As a result, we 
observed significant improvement in cardiac function upon MP-mediated delivery of 
these factors to infarcted hearts. Finally, we investigated the underlying mechanisms 
contributing to this positive effect, especially those linked to endogenous regenerative 
capacity.  
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2. Materials and methods 
All animal procedures were approved by the University of Navarra Institutional 
Committee on Care and Use of Laboratory Animals as well as the European 
Community Council Directive Ref. 86/609/EEC. An expanded Methods section is 
available in the Supplementary Material. 
 
2.1. Materials  
Recombinant human FGF-1 and NRG-1 were supplied from ImmunoTools GmbH 
(Friesoythe, Germany). PLGA with a monomer ratio (lactic acid/ glycolic acid) of 50:50 
Resomer® RG 503H (Mw: 34 kDa) was provided by Boehringer-Ingelheim (Ingelheim, 
Germany). Polyethylene glycol (PEG; Mw: 400), human serum albumin (HSA), bovine 
serum albumin (BSA), dimethylsulfoxide (DMSO) and sodium azide were provided by 
Sigma-Aldrich (Barcelona, Spain). Dichloromethane and acetone were obtained from 
Panreac Quimica S.A. (Barcelona, Spain). Poly(vinyl alcohol) (PVA) 88% hydrolyzed 
(Mw: 125,000) was obtained from Polysciences, Inc. (Warington, USA). Murine HL-1 
cardiomyocyte-cell line (kindly donated by Dr. Claycomb, Louisiana State University 
Medical Center, USA) was used in the in vitro assays. Claycomb medium was provided 
by SAFC Biosciences (Lenexa, KS, USA) and 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium (MTS) was purchased 
from Promega (Madison, USA). Rabbit polyclonal anti-human FGF-1 antibody 
(ab9588) was supplied by Abcam (Cambridge, UK) and horseradish-peroxidase 
conjugated donkey anti-rabbit (NA934V) were purchased from GE Healthcare. Goat 
polyclonal anti-human NRG-1 antibody (sc-1793) and horseradish-peroxidase-
conjugated donkey anti-goat IgG (sc-2020) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). ECL™ anti-rat IgG horseradish peroxidase-
linked whole antibody was from Amersham Biosciences (Buckinghamshire, UK). 
Monoclonal anti-alpha smooth muscle actin-Cy3 (C6198) was provided by Sigma (St. 
Louis, MO, USA), anti-caveolin-1 and rat anti mouse CD45 (550539) from BD 
Pharmingen (Heidelberg, Germany). Rabbit polyclonal anti-human c-Kit antibody 
(A4502) was supplied from Dako (Carpinteria, CA, USA), monoclonal anti-human Ki-
67 antibody (RM9106) was purchased from Thermo Fisher Scientific (Fremont, CA, 
USA) and mouse monoclonal cardiac troponin I antibody (ab19615) was obtained from 
Abcam (Cambridge, UK). DAPI nucleic acid stain was supplied from Molecular 
Probes-Invitrogen (Carlsbad, CA, USA) and TOPRO-3 was from Molecular Probes. 
 
2.2. Preparation and characterization of MPs containing FGF1 and NRG1 
FGF1- and NRG1-loaded PLGA MPs were prepared through a solvent 
extraction/evaporation method using the Total Recirculation One Machine System 
(TROMS) [14]. Particle size and size distribution were measured by laser 
diffractometry. Cytokine encapsulation efficiency and in vitro release from MPs was 
quantified by western blot. Bioactivity of MP-released proteins was evaluated in vitro 
by determining HL-1 cardiomyocyte proliferative capacity following growth factor 
treatment. 
 
2.3. MI model and intramyocardial administration of MPs 
Seventy-three female Sprague-Dawley rats underwent permanent left anterior 
descending coronary artery occlusion to induce MI. Among the surviving animals 
(n=57), only those with a left ventricular ejection fraction (LVEF) below 50% (n=46) at 
2 days post-MI were included in the study. Four days post-MI, rats were divided into 
four groups, and the chests were reopened. Two milligrams of FGF1-loaded MPs 
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(FGF1-MP; 1,740 ng of FGF1), NRG1-loaded MPs (NRG1-MP; 1,300 ng of NRG1), a 
mixture of MPs loaded with FGF1 and NRG1 (FGF1/NRG1-MP; loaded with the same 
doses), or control non-loaded MPs (NL-MP) were injected with a 29-gauge needle into 
four regions surrounding the border of the infarct. At 1 week (n=6 rats) and 3 months 
(n=40 rats) post-injection the animals were sacrificed. 
 
2.4. Morphometric and histological studies 
Heart function was assessed 3 months post-treatment. In addition, heart tissue 
remodeling, revascularization, cardiac proliferation, and endogenous stem cells were 
investigated. All results obtained from the growth factor-treated groups were compared 
to the NL-MP-injected control group. 
 
2.5. Statistical analysis 
Results are expressed as mean ± SEM. Statistics were calculated using Prism 5.0 
software (Graphpad Software Inc., San Diego, CA, USA). P values <0.05 were 
considered significant. 
 
3. Results 
3.1. FGF1 and NRG1 induce adult cardiomyocyte proliferation and survival in vitro  
The effect of FGF1 and/or NRG1 on adult cardiomyocyte proliferation and apoptosis 
was studied in vitro. Treatment of HL-1 cardiomyocytes with different doses of FGF1 
or NRG1 (alone or in combination) led to a statistically significant increase in cell 
proliferation (Figure 1A) (P<0.01). HL-1 cell apoptosis could be induced by hypoxia 
and serum deprivation, and addition of both FGF1 and NRG1 resulted in a statistically 
significant decrease in the apoptotic phenotype (Figure 1B and 1C). 
 
 
Figure 1: FGF1 and NRG1 effects on cardiomyocyte proliferation and apoptosis in vitro 
(A) HL-1 cardiomyocyte proliferation following treatment with free FGF1 or free NRG1 (1, 10, 25, and 
100 ng/ml) administered alone or in combination (FGF1/NRG1). (B,C) HL-1 cell apoptosis in the 
presence of FGF1, NRG1, or FGF1/NRG1 was measured by ELISA detection of histone-associated DNA 
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fragmentation (B) or detection of caspase-3/7 activity (C). Data are expressed as mean ± SEM from three 
independent experiments (*P<0.05, **P<0.01, and ***P<0.001 vs. control).  
 
3.2. Formulation and characterization of FGF1- and NRG1-loaded MPs 
MPs prepared by TROMS had a spherical shape with an average size of 5.1±1.4 µm 
(Figure 2A). Encapsulation efficiency was found to be 87.4±2.3% for FGF1 and 
65.5±5.1% for NRG1, which corresponded to final loading of 874.1±23.4 ng of FGF1 
and 655.3±50.1 ng of NRG1 per mg of polymer. In vitro growth factor release profiles 
revealed an initial burst effect, which indicated that both factors displayed very similar 
release rates from day 7 to day 28, with 65% of NRG1 and almost 70% of FGF1 being 
released within 28 days (Figure 2B). Also, we assessed the bioactivity of the MP-
released cytokines by induction of HL-1 proliferation. NRG1 and FGF1, either released 
from the particles or as free cytokines, induced 1.5–1.7 fold increase in HL-1 
proliferation in comparison with controls (NL-MP or no cytokine), indicating that both 
cytokines retained their biological activity after encapsulation into PLGA MPs (Figure 
2C). 
 
Figure 2: Characterization of MPs loaded with FGF1 and NRG1 
(A) Particle size distribution and (B) Scanning electron microscopy images of MPs loaded with FGF1. 
(C) FGF1 and NRG1 in vitro release from MPs. (D) HL-1 cells were cultured in the presence of either 
MP-released or free FGF1 and NRG1 (100 ng/ml) and cell proliferation was assessed at 72 hours using an 
MTS assay. Data are expressed as mean ± SEM from three independent experiments (**P<0.01 and 
***P<0.001).  
 
3.3. Treatment with FGF1- and NRG1-loaded MPs improved cardiac function in a 
rat model of acute MI 
Next, we investigated the effect of the growth factor-loaded MPs on cardiac repair using 
a rat model of acute MI. Four days after inducing MI, rats were treated with FGF1-MP, 
NRG1-MP, FGF1/NRG1-MP, or control (NL-MP). Three months after transplant, we 
observed significant improvement in LVEF of animals treated with FGF1-MP and 
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NRG1-MP compared to those injected with NL-MP (Table 1). Moreover, absolute 
changes in LVEF (3 months post-infarction LVEF – baseline infarction LVEF) were 
significantly greater in the rats treated with FGF1-MP (15.0 ± 4.9%, P<0.05), NRG1-
MP (18.0 ± 5.7%, P<0.05) or FGF1/NRG1-MP (13.0 ± 1.9%, P<0.05) when compared 
with the NL-MP group (1.1 ± 3.6%) and similar among the three growth factor-loaded 
MP treatments (P=NS).. Left ventricular end-systolic and end-diastolic diameters and 
volumes were higher in the NL-MP group, consistent with left ventricular (LV) 
chamber dilatation and progression of myocardial dysfunction (see Table 1; LVEDV, 
LVESV, LVEDD, and LVESD). In contrast, a statistically significant improvement in 
LVEDV and LVESV as well as LV mass was observed in FGF1-MP, NRG1-MP, and 
FGF1/NRG1-MP treated animals in comparison with NL-MP, indicating a beneficial 
effect on heart remodeling (Table 1). 
Three months following transplantation, infarct size was significantly reduced in 
animals treated with growth factor loaded MPs in comparison with NL-MP (NL-MP: 
16.8±2.8%; FGF1-MP: 11.9±3.8%, P<0.01; NRG1-MP: 12.3±3.6%, P<0.01; 
FGF1/NRG1-MP: 11.7±3.8%, P<0.01) (Figure 3A), but no differences were detected 
among the growth factor treated rats. Similarly, fibrosis (collagen deposition) was 
significantly reduced in animals treated with FGF1-MP, NRG1-MP, or FGF1/NRG1-
MP when compared with the NL-MP group (Figure 3B), whereas LV thickness was 
significantly increased in the animals treated with FGF1-MP (2.06±0.18mm, P<0.05), 
NRG1-MP (1.67±0.07mm, P=0.05), and FGF1/NRG1-MP (1.93±0.14mm, P<0.05) 
compared with control (NL-MP: 1.55±0.14mm).  
 
Table 1: Cardiac function data by echocardiography 
 NL-MP FGF1-MP NRG1-MP FGF1/NRG1-MP 
LVEF 
Baseline 
Day 90 
 
38.0±2.6 
39.1±3.0 
 
29.2±2.9 
44.2±4.0* 
 
30.1±4.1 
48.1±3.1* 
 
38.4±4.7 
51.4±4.9** 
FS 
Baseline 
Day 90 
 
14.4±1.9 
16.8±1.5 
 
11.9±1.3 
19.4±2.1* 
 
12.4±2.0 
21.4±1.7* 
 
16.2±2.2 
23.0±2.8** 
LV mass 
Baseline 
Day 90 
 
1.35±0.04 
1.78±0.07** 
 
1.48±0.07      
1.39±0.07 
 
1.63±0.16 
1.41±0.06 
 
1.46±0.09 
1.44±0.06 
LVEDV 
Baseline 
Day 90 
 
1.151±0.119      
1.916±0.194** 
 
1.364±0.098 
1.225±0.170 
 
1.690±0.219 
1.154±0.088* 
 
1.454±0.190 
1.177±0.110 
LVESV 
Baseline 
Day 90 
 
0.756±0.083 
1.186±0.158* 
 
0.963±0.073 
0.721±0.131 
 
1.159±0.153 
0.614±0.058* 
 
0.912±0.134   
0.585±0.072** 
LVEDD 
Baseline 
Day 90 
 
0.800±0.031 
0.965±0.037** 
 
0.855±0.023 
0.810±0.045 
 
0.912±0.053 
0.788±0.039 
 
0.868±0.043 
0.809±0.028 
LVESD 
Baseline 
Day 90 
 
0.685±0.030 
0.804±0.039* 
 
0.753±0.022 
0.658±0.049 
 
0.796±0.044 
0.642±0.021* 
 
0.729±0.624 
0.624±0.030* 
LVEF: left ventricular ejection fraction (%); FS: fractional shortening (%); LV mass: left ventricular 
mass (g); LVEDV: left ventricular end-diastolic volume (ml); LVESV: left ventricular end-systolic 
volume (ml); LVEDD: left ventricular end-diastolic diameter (cm); LVESD: left ventricular end-systolic 
diameter (cm). Values (mean ± SEM); *P<0.05, **P<0.01, vs. NL-MP. 
 
Next, we evaluated the effect of growth factor loaded MPs on the number of 
arterioles/arteries (alpha smooth muscle actin [α-SMA]-coated vessels) and capillaries 
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(small caliber caveolin-1
+
 vessels). The density of α-SMA+ vessels was significantly 
greater in animals treated with FGF1-MP and/or NRG1-MP (Figure 4A). In addition, 
we observed a significant increase in the area of α-SMA+ vessels after administration of 
any of the cytokine loaded MPs in comparison with the NL-MP (FGF1-MP: 5519±448 
μm2; NRG1-MP: 8489±803 μm2; FGF1/NRG1-MP: 8064±925 μm2; NL-MP: 3972±779 
μm2; P<0.05). 
 
Figure 3: Cardiac remodeling was inhibited by treatment with growth factor-loaded MPs 
Representative images and quantification of infarct size (% of left ventricular [LV] infarcted area vs. total 
LV area) (A) and fibrosis (B) as measured by Sirius Red staining 3 months after injection of growth 
factor-loaded MPs or NL-MP. Results are shown as mean ± SEM (**P<0.01 vs. NL-MP). Scale bars: 1 
mm (A), 200 µm (B).   
 
Also, significantly more capillaries were found in the infarcted and peri-infarcted zones 
of animals treated with NRG1-MP or FGF1/NRG1-MP in comparison with NL-MP, 
whereas FGF1-MP treatment alone did not yield a similar effect (Figure 4B). Notably, 
we observed a negative correlation between LVEF and the degree of fibrosis (R=–
0.599; p=0.002), while there was a positive correlation of LVEF with vasculogenesis 
(the area occupied by α-SMA-coated vessels) (R=0.591; p=0.002) (Table 2). 
 
Figure 4: FGF1 and NRG1 released from MPs in the ischemic myocardium exerted arteriogenic 
and angiogenic effects 
Representative images and quantification of α-SMA+ vessel density (arteriogenesis) (A) and caveolin-1+ 
vessels (capillary staining) (B) in infarcted and peri-infarcted zones 3 months after injection of growth 
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factor-loaded MPs or NL-MP. Results are shown as mean ± SEM (*P<0.05 and **P<0.01 vs. NL-MP 
control group). Scale bars: 50 µm. 
 
Table 2: Pearson correlation analysis between functional echocardiographic parameters and 
histological results of growth factor loaded MP-treated hearts 
 Fibrosis Vessel Area Apoptosis 
Ejection fraction -0.599(p=0.002)** 0.591(p=0.002)** -0.364(p=0.081) 
LVESV  0.543(p=0.006)** -0.428(p=0.037)*  0.517(p=0.010)** 
Data are shown as correlation coefficient (significance). LVESV: Left ventricular end-systolic volume 
(ml). 
 
3.4. Apoptosis of cardiomyocytes is attenuated by growth factor-loaded MPs 
Three months after treatment, there was a similar percentage of TUNEL-positive, 
apoptotic cardiomyocytes detected in the peri-infarcted zones of hearts treated with 
FGF1-MP, NRG1-MP, or control (NL-MP: 2.8±0.9%; FGF1-MP: 1.5±0.2%, P=NS; 
NRG1-MP: 1.8±0.6%; P=NS); however, there was a clear trend in cardiomyocyte 
protection observed when the combination of growth factors was used (NL-MP: 
2.8±0.9% vs. FGF1/NRG1-MP: 1.1±0.3%; P=0.08). Therefore, consistent with the in 
vitro experiments (Figure 1B and 1C), these findings suggest that dual treatment with 
NRG1 and FGF1 has a protective effect. 
 
3.5. Growth factor-loaded MPs promote cardiomyocyte proliferation  
In vivo, NRG1 and FGF1 were reported to induce proliferation of cardiomyocytes.[19, 
24] Thus, to determine whether growth factor loaded MPs could have a similar effect, 
expression of Ki67 was examined in myocyte-specific enhancer factor 2c (MEF2c)
+
 and 
cardiac troponin-T (cTnT)
+
 cardiomyocytes. We observed a significant increase in the 
number of Ki67
+ 
cardiomyocytes in the infarcted and peri-infarcted zones following 
treatment with NRG1-MP compared with NL-MP at 1 week (Figure 5A) and 3 months 
(Figure 5B) post-implantation (1.5- and 3.4-fold increases in Ki67
+ 
cardiomyocytes/mm
2
 at 1 week and 3 months, respectively). 
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Figure 5: Growth factor-loaded MPs induced cardiomyocyte proliferation 
Proliferating cardiomyocytes were measured 1 week (MEF2c
+
/Ki67
+
) after NRG1-MP or NL-MP 
injection (A) or 3 months (cTnT
+
/Ki67
+
) after FGF1-MP, NRG1-M, FGF1/NRG1-MP or NL-MP 
injection (B). Representative images and quantification are shown. Data are represented as mean±SEM 
(*P<0.05 and **P<0.01 vs. NL-MP control group). Scale bars: 20 µm. 
 
3.6. NRG1-MP induced c-Kit
+
/CD45
–
 progenitor cell recruitment during early 
myocardial repair 
Finally, we investigated the effect of growth factor-loaded MPs on cardiac progenitor 
cell recruitment by measuring the number of c-Kit
+
 cells in ischemic myocardium. 
Although the majority of c-Kit
+
 cells in the peri-infarct and infarct zones were CD45
– 
one week after treatment, c-Kit
+
/CD45
+
 cells represented the largest c-Kit
+
 population at 
3 months (Figure 6). Notably, NRG1-MP injection into the ischemic myocardium 
resulted in a significant 10-fold increase in c-Kit
+
/CD45
–
 progenitor cell recruitment 
compared to the control group during the early phase of myocardial repair (1 week after 
MP injection) (NL-MP: 4.88±1.14 c-Kit
+
/CD45
–
 cells/mm
2
; NRG1-MP: 48.40±3.73 c-
Kit
+
/CD45
–
 cells/mm
2
, P<0.001), but not at 3 months post injection (Figure 6). In fact, 
the number of c-Kit
+
/CD45
–
 cells detected at 3 months was much lower than at 1 week. 
These results suggested a transient recruitment of cardiac progenitors shortly after 
injury. Moreover, when c-Kit
+
/CD45
+ 
cells were quantified 1 week and 3 months after 
injection, we observed no significant differences between the groups that received 
growth factor-loaded MPs and NL-MP. 
Figure 6: NRG1-MP treatment induced cardiac progenitor cell recruitment  
Cardiac progenitor cell (c-Kit
+
/CD45
+
 and c-Kit
+
/CD45
–
) recruitment was assessed 1 week after injection 
of NRG1-MP or NL-MP (A,B) and 3 months after injection of NRG1-MP, FGF1-MP, NRG1/FGF1-MP 
or NL-MP (C,D). Representative immunofluorescence images (A,C) and quantitation (B,D) are shown. 
Data are represented as mean±SEM (*P<0.05 and **P<0.01 vs. NL-MP control group). 
 
4. Discussion 
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Protein therapies have failed to show consistent benefits in clinical trials of ischemic 
cardiovascular diseases [4, 28]. Therefore, efforts aimed at understanding the factors 
limiting these strategies are fundamental for the successful development of future 
protein-based approaches. Our findings have suggested that PLGA MPs loaded with 
NRG1 and FGF1 can be used to improve cardiac function after acute MI by inducing an 
increase in vasculogenesis, inhibiting cardiac remodeling, and recruiting c-Kit
+
 cardiac 
progenitors. Thus, the combination of this clinically applicable platform for drug 
delivery along with proteins involved in cardiac biology may represent a new 
therapeutic approach, which overcomes some of the classical drawbacks of protein 
therapy. 
A number of studies have investigated systems that allow controlled delivery of 
therapeutic proteins, such as hydrogels, peptide nanofibers, liposomes, nanoparticles, 
and MPs. These strategies have been used mainly for the delivery of VEGF [14, 29-31], 
FGF1 [19] and FGF2 [32, 33]. Although hydrogels represent an appealing class of 
delivery vehicles, technical difficulties related to injection of the gelatin hydrogel into 
the thin ventricular wall of infarcted rat hearts have been reported [34]. Moreover, while 
liposomes have been shown to accumulate experimentally in areas of MI [30, 35, 36], 
their clinical application has been hindered because they are unstable and readily 
interact with high-density lipoproteins in blood. Also, self-assembling nanofiber 
scaffolds coated with VEGF were recently shown to improve cardiac function in rat and 
pig models of MI by inducing arteriogenesis and recruitment of endogenous 
myofibroblasts and cardiomyocyte-like cells [37]. In contrast to some of these systems, 
PLGA MPs are advantageous because they allow local drug delivery over an extended 
period of time. In fact, we have shown that these MPs persist in heart tissue for at least 
90 days following implantation, favoring long-term growth factor therapy [38]. The 
importance of this sustained release is supported by the fact that previous studies 
analyzing intravenous injection of free NRG1 did not observe improvements in infarct 
size [22], supporting the benefit of using PLGA MPs for delivery. Furthermore, while 
MPs were implanted by direct injection in this study, the size of the particles employed 
should allow for delivery through a less invasive procedure, such as using a NOGA-
guided catheter. Thus, future studies validating this system in larger models might pave 
the way for future clinical application of this strategy, which should be relatively 
straightforward since PLGA has already been approved for clinical use. 
NRG1 regulates cardiovascular homeostasis during development and adulthood by 
stimulating recruitment and proliferation of cardiac progenitors and cardiomyocytes as 
well as inducing angiogenesis, vasculogenesis, and cardiac remodeling [24]. On the 
other hand, FGF1 is a potent cardiac mitogen capable of reducing damage-induced 
cardiac scarring [19]. Based on the putative activities of these two growth factors, we 
hypothesized that a combination therapy involving administration of both cytokines 
would be more beneficial than each individually; however, we did not observe a 
consistent synergistic effect in vitro or in vivo. Instead, we observed that the effect of 
both cytokines combined was lower than either alone. Thus, as both proteins may utilize 
similar signaling pathways [15, 17], it is possible that they compete, limiting their 
combined effect. Indeed, this important observation should be considered when 
designing new studies involving combination therapies. Interestingly, even though the 
cytokines showed an additive effect in preventing cardiomyocyte apoptosis in vitro, this 
finding did not translate in vivo.  
Further elucidation of the mechanisms by which different growth factors contribute to 
cardiac repair should help to refine protein-based therapies, as cytokines with different 
functional mechanisms may act synergistically. Interestingly, when tissue 
12 
 
revascularization was assessed, a significant increase in arteriolar/arteries density and 
capillaries were found after treatment in each of the groups treated with growth factor-
loaded MPs. These effects were only significant in those groups treated with NRG1, 
suggesting that at least in vivo, NRG1 has a greater vasculogenic effect in comparison 
with FGF1. While various populations of cardiac progenitor cells have been described, 
one of the most commonly employed cardiac progenitor markers is c-Kit, which 
identifies cells that participate in endogenous cardiac repair following MI [39]. Indeed, 
we identified a dramatic 10-fold increase in the number of c-Kit
+
/CD45
–
 progenitor 
cells 7 days after injection of NRG1-loaded MPs, which coincided with the time when 
the most drug was released from MPs. Thus, this finding suggests a potential role for 
NRG1 in cardiac progenitor recruitment. Moreover, it has been reported that c-Kit
+
 
progenitor cells can present a vascular phenotype, which might suggest that they 
participate in de novo vessel formation [40]. Nevertheless, we did not detect the 
recruitment of specific progenitors with a vascular phenotype.  
In addition to cardiac progenitors, recent studies have suggested that adult 
cardiomyocytes can contribute directly to cardiac regeneration through either 
proliferation or dedifferentiation processes [41, 42]. Thus, targeting cardiomyocyte 
proliferation could also represent a useful therapeutic approach. Although our study was 
not designed to specifically investigate cardiomyocyte proliferation, we observed 
increased Ki67
+
 in cardiomyocytes 1 week and 3 months after injection of growth 
factor-loaded MPs, suggesting that a sustained release of NRG1 and FGF1 may increase 
the in vivo proliferative potential of myocytes. As observed in the case of c-Kit
+
 
progenitors, the effect on myocyte proliferation was negligible at 3 months but was 100-
fold higher 1 week after injection.  
 
5. Conclusions 
Taken together, our present findings demonstrate the therapeutic efficacy of combining 
sustained protein delivery platforms with growth factors for achieving cardiac 
regeneration. Specifically, we have successfully delivered FGF1 and NRG1 to ischemic 
myocardium using a slow-release polymer. This strategy significantly contributed to 
global myocardial function during post-MI remodeling by promoting angiogenesis and 
arteriogenesis, inducing cardiac proliferation, and eliciting stem cell recruitment. 
Further validation of this therapeutic approach in large preclinical models could pave 
the way for implementation of this strategy in patients with ischemic heart disease. 
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